Trial Profile
European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions; Therapeutic Use
- 10 Feb 2011 New trial record